ID19886A - Terapi gabungan untuk osteoporosis - Google Patents
Terapi gabungan untuk osteoporosisInfo
- Publication number
- ID19886A ID19886A IDP970570A ID970570A ID19886A ID 19886 A ID19886 A ID 19886A ID P970570 A IDP970570 A ID P970570A ID 970570 A ID970570 A ID 970570A ID 19886 A ID19886 A ID 19886A
- Authority
- ID
- Indonesia
- Prior art keywords
- osteoporosis
- combined therapy
- therapy
- combined
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1241296P | 1996-02-28 | 1996-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID19886A true ID19886A (id) | 1998-08-13 |
Family
ID=21754846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDP970570A ID19886A (id) | 1996-02-28 | 1997-02-26 | Terapi gabungan untuk osteoporosis |
Country Status (45)
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
AR008155A1 (es) * | 1996-09-06 | 1999-12-09 | Smithkline Beecham Corp | Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres. |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
US6531485B2 (en) | 1997-06-23 | 2003-03-11 | Pfizer Inc. | Prostaglandin agonists |
JP2001515863A (ja) * | 1997-09-09 | 2001-09-25 | ザ プロクター アンド ギャンブル カンパニー | 骨体積増加方法 |
UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
EP0950417A3 (en) * | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
BR9911615A (pt) * | 1998-06-03 | 2001-02-06 | Pfizer Prod Inc | 2-aminopiridinas contendo substituintes de anel fundido como inibidores de sintase de óxido nìtrico |
DK0966968T3 (da) * | 1998-06-16 | 2004-08-30 | Pfizer Prod Inc | Terapeutiske kombinationer, der omfatter en selektiv östrogenreceptormodulator og prostaglandin E2 |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
EA200001189A1 (ru) * | 1998-06-16 | 2001-06-25 | Пфайзер Продактс Инк. | Терапевтические комбинации (избирательных) модуляторов рецепторов эстрогенов (имрэ) и стимуляторов секреции гормона роста (ссгр) для лечения скелетно-мышечной слабости |
AP9901582A0 (en) * | 1998-06-16 | 1999-06-30 | Pfizer Prod Inc | Combination therapy for musculoskeletal frailty. |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
US6414006B1 (en) | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
TR200200436T2 (tr) * | 1998-11-03 | 2002-06-21 | Pfizer Inc. | Yeni makrolit antibiyotikler |
NZ513827A (en) * | 1999-03-05 | 2001-09-28 | Procter & Gamble | Methods of increasing bone volume using non-naturally-occurring FP selective agonists and antiresorptive compounds |
GB9913649D0 (en) * | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
DE60101206T2 (de) * | 2000-06-01 | 2004-09-02 | Watson Pharmaceuticals, Inc., Corona | Transdermale verabreichung von lasofoxifen |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
ES2233570T3 (es) * | 2000-11-30 | 2005-06-16 | Pfizer Products Inc. | Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona. |
SK622004A3 (en) * | 2001-07-31 | 2004-08-03 | Pfizer Prod Inc | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
TWI316511B (en) * | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
AU2012315782B2 (en) | 2011-09-30 | 2015-10-29 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
CN103142644B (zh) * | 2013-03-21 | 2014-07-23 | 青岛正大海尔制药有限公司 | 骨化三醇和氟化钠的混悬颗粒及其制备方法 |
EP3525774B1 (en) | 2016-10-11 | 2021-12-29 | Duke University | Lasofoxifene treatment of er+ breast cancer |
CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
WO2019204985A1 (zh) * | 2018-04-24 | 2019-10-31 | 深圳华大生命科学研究院 | 骨质疏松生物标志物及其用途 |
CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3234090A (en) | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
BE637389A (zh) | 1962-09-13 | |||
US3522319A (en) | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
US3927197A (en) | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
US3932389A (en) | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
US4018892A (en) | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4000309A (en) | 1975-08-06 | 1976-12-28 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US3982016A (en) | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4132847A (en) | 1977-07-22 | 1979-01-02 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
EP0002097B1 (en) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
US4097601A (en) | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US4171331A (en) | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4621100A (en) | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
EP0162510B1 (en) | 1984-04-30 | 1991-08-28 | THE PROCTER & GAMBLE COMPANY | Kit for use in the treatment of osteoporosis |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
DE3762617D1 (de) | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
US5216183A (en) | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
EP0559751B1 (en) | 1990-11-26 | 1997-03-26 | RECKER, Robert R. | Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5180720A (en) * | 1991-05-03 | 1993-01-19 | G. D. Searle & Co. | 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain |
US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
PL176993B1 (pl) | 1992-12-11 | 1999-08-31 | Merck & Co Inc | Nowe związki spiropiperydynowe oraz sposób ich wytwarzania |
US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
TW303299B (zh) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
CA2173333A1 (en) * | 1993-10-19 | 1995-04-27 | Barry J. Gertz | Combination of bisphosphonates and growth hormone secretagogues |
US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
AU1172995A (en) | 1993-11-09 | 1995-05-29 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
CA2176140A1 (en) | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
US5441966A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
AU2695795A (en) | 1994-06-13 | 1996-01-05 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
JPH10505091A (ja) * | 1994-09-09 | 1998-05-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 骨粗鬆症用のホスホネート及び副甲状腺ホルモン |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
US6100301A (en) | 1996-02-28 | 2000-08-08 | Pfizer Inc | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists |
IL120270A0 (en) | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
SI0904273T1 (en) | 1996-05-07 | 2003-08-31 | Pfizer Inc. | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist |
KR20000016204A (ko) | 1996-05-31 | 2000-03-25 | 한센 핀 베네드, 안네 제헤르 | 골다공증의 주기적(연계) 치료에 있어 성장호르몬 성분 및 뼈의항흡수 약물 |
GB2324726A (en) | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
UA53716C2 (uk) * | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
BR9803596A (pt) | 1997-09-23 | 2000-04-25 | Pfizer Prod Inc | Derivados do resorcinol. |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
-
1996
- 1996-12-19 HN HN1996000101A patent/HN1996000101A/es unknown
- 1996-12-20 TW TW085115770A patent/TW464496B/zh not_active IP Right Cessation
- 1996-12-23 PT PT96941153T patent/PT883404E/pt unknown
- 1996-12-23 AU AU10398/97A patent/AU703285B2/en not_active Ceased
- 1996-12-23 EP EP08002426A patent/EP1932543A3/en not_active Withdrawn
- 1996-12-23 IL IL15437996A patent/IL154379A0/xx unknown
- 1996-12-23 SK SK1183-98A patent/SK118398A3/sk unknown
- 1996-12-23 UA UA98073901A patent/UA69372C2/uk unknown
- 1996-12-23 IL IL12549396A patent/IL125493A0/xx unknown
- 1996-12-23 US US09/117,972 patent/US6323232B1/en not_active Expired - Fee Related
- 1996-12-23 AT AT96941153T patent/ATE405273T1/de not_active IP Right Cessation
- 1996-12-23 CN CNA2003101202337A patent/CN1515254A/zh active Pending
- 1996-12-23 NZ NZ323456A patent/NZ323456A/xx unknown
- 1996-12-23 TR TR1998/01679T patent/TR199801679T2/xx unknown
- 1996-12-23 CN CNB961800585A patent/CN1242813C/zh not_active Expired - Fee Related
- 1996-12-23 KR KR1019980706746A patent/KR19990087337A/ko active Search and Examination
- 1996-12-23 DK DK96941153T patent/DK0883404T3/da active
- 1996-12-23 SI SI9630762T patent/SI0883404T1/sl unknown
- 1996-12-23 EP EP02010920A patent/EP1236475A3/en not_active Ceased
- 1996-12-23 CZ CZ0271898A patent/CZ297452B6/cs not_active IP Right Cessation
- 1996-12-23 EP EP96941153A patent/EP0883404B1/en not_active Expired - Lifetime
- 1996-12-23 PL PL35998796A patent/PL187962B1/pl not_active IP Right Cessation
- 1996-12-23 JP JP9530738A patent/JPH11504352A/ja active Pending
- 1996-12-23 WO PCT/IB1996/001462 patent/WO1997031640A1/en active IP Right Grant
- 1996-12-23 RU RU98117620/14A patent/RU2190395C2/ru not_active IP Right Cessation
- 1996-12-23 HU HU9904123A patent/HUP9904123A3/hu unknown
- 1996-12-23 BR BR9612533A patent/BR9612533A/pt not_active Application Discontinuation
- 1996-12-23 CN CNA2003101202356A patent/CN1515317A/zh active Pending
- 1996-12-23 IL IL15438096A patent/IL154380A0/xx unknown
- 1996-12-23 CN CNA2003101202341A patent/CN1515316A/zh active Pending
- 1996-12-23 DE DE69637651T patent/DE69637651D1/de not_active Expired - Lifetime
- 1996-12-23 CN CNA2003101202360A patent/CN1515258A/zh active Pending
- 1996-12-23 PL PL96328831A patent/PL187219B1/pl not_active IP Right Cessation
- 1996-12-23 CA CA2247420A patent/CA2247420C/en not_active Expired - Fee Related
- 1996-12-23 ES ES96941153T patent/ES2312169T3/es not_active Expired - Lifetime
-
1997
- 1997-01-16 GT GT199700009A patent/GT199700009A/es unknown
- 1997-02-13 CO CO97007548A patent/CO4761063A1/es unknown
- 1997-02-24 PE PE2001000871A patent/PE20011302A1/es not_active Application Discontinuation
- 1997-02-24 AR ARP970100746A patent/AR005987A1/es not_active Application Discontinuation
- 1997-02-24 PE PE1997000128A patent/PE58998A1/es not_active Application Discontinuation
- 1997-02-26 TN TNTNSN97040A patent/TNSN97040A1/fr unknown
- 1997-02-26 DZ DZ970032A patent/DZ2186A1/fr active
- 1997-02-26 ID IDP970570A patent/ID19886A/id unknown
- 1997-02-26 MA MA24508A patent/MA26420A1/fr unknown
- 1997-02-27 AP APAP/P/2000/001962A patent/AP975A/en active
- 1997-02-27 HR HR60/012,412A patent/HRP970118A2/xx not_active Application Discontinuation
- 1997-02-27 AP APAP/P/1997/000934A patent/AP974A/en active
- 1997-02-27 YU YU7797A patent/YU7797A/sh unknown
- 1997-02-27 ZA ZA971719A patent/ZA971719B/xx unknown
- 1997-02-27 UY UY2447224472A patent/UY24472A1/es not_active IP Right Cessation
- 1997-08-01 GT GT199700009AK patent/GT199700009AA/es unknown
-
1998
- 1998-07-28 IS IS4812A patent/IS4812A/is unknown
- 1998-08-14 OA OA9800142A patent/OA10837A/en unknown
- 1998-08-26 BG BG102726A patent/BG64582B1/bg unknown
- 1998-08-27 NO NO19983936A patent/NO323648B1/no not_active IP Right Cessation
-
1999
- 1999-07-28 HK HK99103244A patent/HK1018210A1/xx not_active IP Right Cessation
-
2000
- 2000-12-13 US US09/736,051 patent/US7255984B2/en not_active Expired - Fee Related
-
2002
- 2002-02-28 JP JP2002054756A patent/JP2002308771A/ja active Pending
- 2002-11-07 AP APAP/P/2002/002661A patent/AP1179A/en active
-
2004
- 2004-01-27 CL CL200400119A patent/CL2004000119A1/es unknown
-
2006
- 2006-08-29 NO NO20063853A patent/NO20063853L/no not_active Application Discontinuation
-
2007
- 2007-05-03 AR ARP070101915A patent/AR060853A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID19886A (id) | Terapi gabungan untuk osteoporosis | |
NO950275D0 (no) | Kombinasjonsbehandling for osteoporose | |
ID24118A (id) | Terapi gabungan | |
DE59700099D1 (de) | Knochenplatte | |
NO992806L (no) | Terapeutiske midler | |
ID24275A (id) | Terapi kombinasi | |
ID19075A (id) | Perangkap tempat kaustik untuk asetaldehida | |
NO983090D0 (no) | Terapeutiske forbindelser | |
DE69823718D1 (de) | Bestrahlungsvorrichtung | |
DE69812879D1 (de) | Patientenliege | |
GB9716344D0 (en) | Therapeutic compounds | |
FI972383A (fi) | Osteoporoosihoitojaksoon tarkoitettu pakkaus | |
GB9626450D0 (en) | Therapeutic compounds | |
KR970053540U (ko) | 침시술용 침관 | |
KR970004260U (ko) | 정형외과용 콜셋 | |
BR7601137U (pt) | Bone | |
ID19095A (id) | Senyawa terapeutik fenetanolamina | |
UA25526A (uk) | Пристрій для електромагhітhої терапії | |
NO965332D0 (no) | Terapeutisk perparat | |
IT241474Y1 (it) | Sottopiede per calzatura | |
NO964439L (no) | Fôr | |
NO960756D0 (no) | For | |
GB9608372D0 (en) | Therapeutic compounds | |
GB9613017D0 (en) | Therapeutic compounds | |
GB9608547D0 (en) | Therapeutic compounds |